Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ZUG, Sviss, April 10, 2025 (GLOBE NEWSWIRE) -- DIAMOND er fyrsta og eina rannsóknaráætlunin sem miðar að skráningu (e. pivotal trial) sem farið hefur fram með staðbundna meðferð við sjónhimnubjúg af...
-
ZUG, Switzerland, April 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company. Attachment ...
-
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing...
-
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing...
-
ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule...
-
ZUG, Switzerland, March 14, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company, as well as...
-
ZUG, Sviss, March 11, 2025 (GLOBE NEWSWIRE) -- Árið 2024 var árangursríkt og einkenndist af verulegum áföngum þróunarlyfja Oculis á síðari stigum klínískra prófana fyrir meðferð á sjúkdómum í...
-
ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting...
-
Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic macular edema), neuro-ophthalmic...
-
ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...